The transaction is part of our strategy to lower interest expense, reduce dilution, and significantly extend debt maturityOffering priced at ...
BridgeBio Pharma plans to offer $500 million in convertible senior notes, aiming to strengthen its financial position and reduce interest expenses. BridgeBio Pharma, Inc. announced plans to offer $500 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results